Oncology News and Research RSS Feed - Oncology News and Research Twitter

Oncology, meaning bulk, mass, or tumor, and the suffix ''-logy'', meaning "study of") is a branch of medicine that deals with tumors (cancer). A medical professional who practices oncology is an ''oncologist''.
DNA analysis reveals how ovarian cancer takes genetic twists and turns to outsmart chemotherapy

DNA analysis reveals how ovarian cancer takes genetic twists and turns to outsmart chemotherapy

The largest complete DNA analysis of ovarian cancer in the world, published overnight in Nature, has revealed unprecedented new insight into the genetic twists and turns a deadly form of the disease takes to outsmart chemotherapy, potentially changing treatment approaches for women around the world. [More]
RPCI researchers develop individualized post-operative survival calculator for colon cancer patients

RPCI researchers develop individualized post-operative survival calculator for colon cancer patients

Roswell Park Cancer Institute researchers have developed an accurate, individualized post-operative survival calculator and integrated the technology into a mobile application compatible with smartphone technology for oncologists and patients diagnosed with colon cancer. Information about the calculator will be presented at the American Society of Clinical Oncology 51st Annual Meeting in Chicago. [More]
Incidence of melanoma on the rise among children and young adults

Incidence of melanoma on the rise among children and young adults

The incidence of melanoma, a deadly form of skin cancer, has increased by more than 250% among children, adolescents and young adults since 1973, according to award-winning research to be presented by Roswell Park Cancer Institute (RPCI) at the American Society of Clinical Oncology (ASCO) 51st Annual Meeting in Chicago. [More]
Monoclonal antibody nivolumab improves survival rates of melanoma patients

Monoclonal antibody nivolumab improves survival rates of melanoma patients

The monoclonal antibody nivolumab has shown promise as a therapeutic agent, particularly by improving the survival rates of melanoma patients. Jeffrey S. Weber, M.D., Ph.D., director of the Donald A. Adam Comprehensive Melanoma Research Center at Moffitt Cancer Center will be presenting data from a retrospective analysis of the safety of nivolumab in 4 ongoing phase I-III studies in melanoma patients at the 2015 American Society of Clinical Oncology Annual Meeting in Chicago. [More]
MEDI4736 and tremelimumab combination shows acceptable safety, potential efficacy in NSCLC patients

MEDI4736 and tremelimumab combination shows acceptable safety, potential efficacy in NSCLC patients

Advanced non-small cell lung cancer (NSCLC) patients have few effective treatment options and low 5-year survival rates. The checkpoint inhibitors MEDI4736 and tremelimumab have both demonstrated acceptable safety and potential efficacy when used as single-agents in several different types of cancer. [More]
JAK2 inhibitor ruxolitinib shows promise in treating CMML patients

JAK2 inhibitor ruxolitinib shows promise in treating CMML patients

Chronic myelomonocytic leukemia (CMML) is a rare type of myelodysplastic, myeloproliferative neoplasm characterized by increased numbers of peripheral monocytes and less than 20 percent blasts. CMML has few treatment options and patients only survive on average for 12 to 24 months. [More]
Green tea components may help prevent prostate cancer development in at-risk men

Green tea components may help prevent prostate cancer development in at-risk men

Prostate cancer is the second most common type of cancer in men and is predicted to result in an estimated 220,00 cases in the United States in 2015. In recent years, an emphasis has been placed on chemoprevention - the use of agents to prevent the development or progression of prostate cancer. [More]
Study: New cases of cancer rising globally, but death rates falling in many countries

Study: New cases of cancer rising globally, but death rates falling in many countries

New cases of virtually all types of cancer are rising in countries globally - regardless of income - but the death rates from cancer are falling in many countries, according to a new analysis of 28 cancer groups in 188 countries. [More]
Boehringer Ingelheim, University of Michigan partner to discover new medicines for diabetic nephropathy

Boehringer Ingelheim, University of Michigan partner to discover new medicines for diabetic nephropathy

Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy. [More]
Janssen, Bayer HealthCare initiate CALLISTO program to study rivaroxaban in patients with active cancer

Janssen, Bayer HealthCare initiate CALLISTO program to study rivaroxaban in patients with active cancer

Janssen Pharmaceuticals, Inc. and its development partner, Bayer HealthCare, today announced the initiation of CALLISTO, a new comprehensive clinical research program for their novel oral anticoagulant, rivaroxaban, in patients with active cancer. The studies are evaluating the medicine for the prevention and treatment of life-threatening blood clots in patients with a wide range of cancer types. [More]
PDS Biotechnology announces positive results from PDS0101 Phase I trial in pre-cervical cancer patients

PDS Biotechnology announces positive results from PDS0101 Phase I trial in pre-cervical cancer patients

PDS Biotechnology Corp. announces preliminary data showing that PDS0101, a cancer immunotherapy treatment targeting HPV-16, has generated strong T-cell responses in pre-cervical cancer patients. [More]
Researchers identify chemical pathway associated with seizures, shorter survival in patients with malignant glioma

Researchers identify chemical pathway associated with seizures, shorter survival in patients with malignant glioma

Researchers at the University of Alabama at Birmingham have identified a chemical pathway that may be associated with seizures and shorter patient survival in some patients with malignant glioma, the most common and deadly form of brain tumor. In findings published May 27 in Science Translational Medicine, the researchers suggest that a transporter known as SXC is responsible for boosting levels of glutamate in the brains of some glioma patients. [More]
EKF Diagnostics highlighting cancer molecular diagnostics products at ASCO 2015

EKF Diagnostics highlighting cancer molecular diagnostics products at ASCO 2015

EKF subsidiary, Selah Genomics’ newly introduced PrecisionPath™ next generation sequencing (NGS) technology cancer test will be a key focus on Booth #19141... [More]
Modest lifestyle changes help breast cancer survivors lose weight

Modest lifestyle changes help breast cancer survivors lose weight

Carrying extra body fat increases the risk for diabetes, heart disease and stroke, and also increases risk of cancer recurrence after a breast cancer diagnosis. A multi-institutional study presented at the American Society for Clinical Oncology Annual Meeting 2015 shows that female breast cancer survivors are able to lose weight through modest lifestyle changes. [More]
Brigatinib drug shows promise against ALK+ non-small cell lung cancer in phase I/II clinical trial

Brigatinib drug shows promise against ALK+ non-small cell lung cancer in phase I/II clinical trial

Phase I/II clinical trial results reported at the American Society for Clinical Oncology (ASCO) Annual Meeting 2015 show promising results for investigational drug brigatinib against ALK+ non-small cell lung cancer (NSCLC), with 58 of 78 ALK+ patients responding to treatment, including 50 of 70 patients who had progressed after previous treatment with crizotinib, the first licensed ALK inhibitor. [More]
AACR, Bayer partner to expand Basic Cancer Research Fellowship Program for 2015

AACR, Bayer partner to expand Basic Cancer Research Fellowship Program for 2015

The American Association for Cancer Research and Bayer HealthCare are pleased to announce a new partnership that will expand AACR's Basic Cancer Research Fellowship Program for 2015. [More]
Children's National Health System first in U.S. to treat osteoid osteoma using MR-HIFU method

Children's National Health System first in U.S. to treat osteoid osteoma using MR-HIFU method

Doctors from the Sheikh Zayed Institute for Pediatric Surgical Innovation at Children's National Health System are the first in the United States to treat osteoid osteoma, a benign but painful bone tumor that commonly occurs in children and young adults, using an experimental magnetic resonance-guided high-intensity focused ultrasound (MR-HIFU) method. [More]
Strand Life Sciences to launch expanded StrandAdvantage pan-cancer genomic profiling service at ASCO 2015

Strand Life Sciences to launch expanded StrandAdvantage pan-cancer genomic profiling service at ASCO 2015

Strand Life Sciences, a global genomic profiling company that uses next generation sequencing technology to empower cancer care, today announced it will introduce its expanded StrandAdvantage pan-cancer genomic profiling service later this month at the 2015 American Society of Clinical Oncology Annual Meeting in Chicago. [More]
Positive clinical data of CytRx's aldoxorubicin to be presented at ASCO 2015

Positive clinical data of CytRx's aldoxorubicin to be presented at ASCO 2015

CytRx Corporation, a biopharmaceutical research and development company specializing in oncology, today announced an upcoming poster presentation regarding its lead drug candidate, aldoxorubicin, at the 2015 American Society of Clinical Oncology Annual Meeting, which is being held May 29 - June 2, 2015 in Chicago. [More]
Clinical utility data for Guardant360 platform to be presented at ASCO 2015

Clinical utility data for Guardant360 platform to be presented at ASCO 2015

Guardant Health today announced that five abstracts submitted by the University of California, San Francisco; University of California, San Diego; and MD Anderson highlighting the performance and clinical utility of Guardant360 have been accepted for oral and poster presentations at the 2015 American Society of Clinical Oncology Annual Meeting in Chicago, May 29-June 2. [More]
Advertisement
Advertisement